ReviewRSC chemical biology2021
Targeting the RNA demethylase FTO for cancer therapy.
Review in RSC chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.Frontiers in pharmacology · 2022Pooled it
- FTO-modulated mJournal of translational medicine · 2026Article
- Structure-based Discovery of a Non-competitive FTO Inhibitor Bound to a Cryptic Site at the Domain Interface.Journal of molecular biology · 2026Article
- NBiomolecules · 2026Review
- Influence of RNA Modifications on Cancer Metabolism: Interplay with Hypoxia and Therapeutic Implications.Advances in experimental medicine and biology · 2026Review
- FTO in cardiovascular diseases: mechanisms, context dependence, and translational opportunities.Frontiers in cell and developmental biology · 2026Review
- Role of m6A RNA methylation regulators in pancreatic cancer: interactions and potential implications.Cancer cell international · 2025Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- Epitranscriptome: A Novel Regulatory Layer during Atherosclerosis Progression.Current medicinal chemistry · 2025Review
- The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy.Frontiers in cell and developmental biology · 2025Review
- Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy.Acta pharmaceutica Sinica. B · 2024Article
- Medicinal chemistry aspects of fat mass and obesity associated protein: structure, function and inhibitors.Future medicinal chemistry · 2024Review
- A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO.RSC chemical biology · 2024Article
- RNA modification: mechanisms and therapeutic targets.Molecular biomedicine · 2023Review
- The roles and implications of RNA mNature reviews. Clinical oncology · 2023Review
- Emerging Role and Mechanism of theBiomolecules · 2023Review
- METTL16 in human diseases: What should we do next?Open medicine (Warsaw, Poland) · 2023Review
- FTO plays a crucial role in gastrointestinal cancer and may be a target for immunotherapy: an updated review.Frontiers in oncology · 2023Review
- Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Rational Design and Optimization of mJournal of medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.